Diadem and the University of Texas Medical Branch report new evidence on Alzheimer’s biomarker at CTAD 2026

Research collaboration with the University of Texas Medical Branch provides further evidence of an apparent relationship between U-p53AZ and tau accumulation, supporting its association with Alzheimer’s disease pathology

MIAMI, FL and MILAN, Italy, November 18 2026

Researchers from Diadem SpA and the University of Texas Medical Branch (UTMB) have reported new findings adding to the evidence linking the U-p53AZ biomarker with Alzheimer’s disease pathology. The findings, which are consistent with previous research suggesting that U-p53AZ may be specific to Alzheimer’s disease, were presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Boston, Massachusetts, from 16–19 November 2026.

Diadem, a diagnostics company developing blood-based technologies for Alzheimer’s disease (AD) and other neurodegenerative conditions, is collaborating with researchers at UTMB to investigate U-p53AZ in human brain tissue. The findings were presented in the poster Exclusive Detection of U-p53AZ in Alzheimer’s Disease Compared to Other Neurodegenerative Diseases (P335). The study builds on earlier work by examining the presence of U-p53AZ in brain tissue from patients with different neurodegenerative conditions, including frontotemporal dementia and dementia with Lewy bodies.

The poster was presented by lead author David Lynch of UTMB’s Mitchell Center for Neurodegenerative Diseases. Shmuel (Sam) Agus, MD, Diadem’s Chief Medical Officer and a co-author of the research, also attended the congress.

Using Diadem’s proprietary 2D3A8 antibody, researchers detected U-p53AZ, a conformationally altered form of the p53 protein, in brain tissue from patients with Alzheimer’s disease. Notably, U-p53AZ seems to co-localize with phosphorylated tau, which is a hallmark of AD, and the extent of accumulation of this variant seems to follow the pattern of tau accumulation, and disease staging. No corresponding staining was observed in the samples examined from patients with frontotemporal dementia or dementia with Lewy bodies, or in healthy controls.

“These findings represent an exciting step forward in our understanding of U-p53AZ and its relationship with Alzheimer’s disease,” said Shmuel (Sam) Agus, MD, Chief Medical Officer of Diadem. “Being able to detect U-p53AZ in Alzheimer’s brain tissue, and its apparent relationship with tau accumulation, provides encouraging evidence of its disease association. The lack of staining in tissue from patients with other types of dementia is also consistent with previous evidence suggesting that U-p53AZ may be specific to AD. Our collaboration with UTMB is helping us deepen the understanding of this distinctive biomarker and further explore its potential to address one of the major challenges in dementia diagnosis: distinguishing Alzheimer’s disease from other neurodegenerative conditions.”

Diadem’s AlzoSure® Predict blood test is based on the proprietary 2D3A8 antibody and measures U-p53AZ, a conformationally altered form of p53 associated with Alzheimer’s

disease. Previous longitudinal clinical research has demonstrated the test’s potential to identify individuals at risk of progressing to Alzheimer’s disease up to six years before clinical diagnosis.

About Alzheimer’s disease

Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. It is a progressive neurodegenerative disease that affects memory, thinking, behaviour, and the ability to carry out everyday activities. Early identification of individuals at increased risk of progression could support timely clinical assessment and decisions about treatment and care.

About Diadem

Diadem was founded as a spin-out of the University of Brescia, Italy. The company is developing blood-based prognostic and diagnostic technologies for Alzheimer’s disease and other neurodegenerative conditions. Its lead product, AlzoSure® Predict, is designed to identify individuals at increased risk of progressing to Alzheimer’s disease before clinical diagnosis.

Media contact

Exec Admin to CEO: execadmin@diademdx.com